We are live on ! Find out more
KERX

Keryx Biopharmaceuticals Inc
KERX

Delisted

KERX was delisted on the 12th of December, 2018.

Back to rankings

1 hedge funds and large institutions have $0 invested in Keryx Biopharmaceuticals Inc in 2018 Q4 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 122 closing their positions.

New
Increased
Maintained
Reduced
Closed

99% less funds holding

Funds holding: 123 → 1 (-122)

100% less capital invested

Capital invested by funds: $253M → $0 (-$253M)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 122

Holders
1
Holders Change
-122
Holders Change %
-99.19%
% of All Funds
0.02%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
122
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
BG
Baupost Group
Massachusetts
-$87.7M
2
ACM
Abrams Capital Management
Massachusetts
-$31M
3
Vanguard Group
Vanguard Group
Pennsylvania
-$28M
4
BlackRock
BlackRock
New York
-$24.5M
5
State Street
State Street
Massachusetts
-$17.5M
Name Holding Trade Value Shares
Change 		Change in
Stake
BG
1
Baupost Group
Massachusetts
– -$87.7M -25,791,678 Closed
ACM
2
Abrams Capital Management
Massachusetts
– -$31M -9,108,867 Closed
Vanguard Group
3
Vanguard Group
Pennsylvania
– -$28M -8,240,391 Closed
BlackRock
4
BlackRock
New York
– -$24.5M -7,199,683 Closed
State Street
5
State Street
Massachusetts
– -$17.5M -5,135,293 Closed
RHJA
6
Rice Hall James & Associates
California
– -$7.58M -2,228,059 Closed
Norges Bank
7
Norges Bank
Norway
– -$6.98M -2,051,899 Closed
PIMJS
8
PKO Investment Management Joint-Stock
Poland
– -$5M -1,469,609 Closed
Northern Trust
9
Northern Trust
Illinois
– -$4.25M -1,250,239 Closed
Geode Capital Management
10
Geode Capital Management
Massachusetts
– -$3.83M -1,125,202 Closed
OWIM
11
Old West Investment Management
California
– -$3.63M -1,068,719 Closed
Bank of New York Mellon
12
Bank of New York Mellon
New York
– -$3.36M -987,204 Closed
Deutsche Bank
13
Deutsche Bank
Germany
– -$2.07M -609,809 Closed
Millennium Management
14
Millennium Management
New York
– -$1.99M -585,406 Closed
Fidelity Investments
15
Fidelity Investments
Massachusetts
– -$1.95M -574,734 Closed
Charles Schwab
16
Charles Schwab
California
– -$1.92M -565,578 Closed
Ameriprise
17
Ameriprise
Minnesota
– -$1.44M -424,071 Closed
Morgan Stanley
18
Morgan Stanley
New York
– -$1.42M -418,255 Closed
Boston Partners
19
Boston Partners
Massachusetts
– -$971K -285,530 Closed
Barclays
20
Barclays
United Kingdom
– -$881K -259,160 Closed
Citigroup
21
Citigroup
New York
– -$789K -232,013 Closed
NC
22
Nexthera Capital
New York
– -$680K -200,000 Closed
RCMNY
23
Rubric Capital Management (New York)
New York
– -$680K -199,883 Closed
TCIM
24
TIAA CREF Investment Management
New York
– -$673K -197,822 Closed
PPA
25
Parametric Portfolio Associates
Washington
– -$659K -193,848 Closed
1
2 3 4 5

KERX Hedge Fund Activity: Q4 2018 in Review

1 of the 4,489 institutional investors tracked by Wall St. Rank reported a position in Keryx Biopharmaceuticals Inc (KERX) for Q4 2018, worth a combined $0 — down 100% from $253M a quarter earlier.

Sellers outnumbered buyers: 122 funds closed out of KERX and 0 opened new positions — a net loss of 122 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was Baupost Group, exiting entirely with an estimated $87.7M sold.

  • 1 institutional investor held Keryx Biopharmaceuticals Inc (KERX) as of Q4 2018, down from 123 in Q3 2018.
  • Funds reported $0 of Keryx Biopharmaceuticals Inc stock for Q4 2018, down 100% quarter-over-quarter.
  • 0 funds opened new Keryx Biopharmaceuticals Inc positions in Q4 2018 and 122 closed out, a net change of -122 holders.
  • The largest Keryx Biopharmaceuticals Inc seller in Q4 2018 was Baupost Group, an estimated $87.7M sold.

Based on aggregated 13F filings for Q4 2018.